DiNAQOR
DiNAQOR is a global gene therapy platform company focused on advancing novel solutions for patients suffering from heart disease. Founded in 2019, it specializes in proprietary human-based tissue drug development and technology to enable organ-specific delivery of gene therapies. The company is headquartered in Switzerland with additional presence in the US and Germany, and aims to develop gene therapy solutions that transform the lives of patients with heart disease.
Industries
Nr. of Employees
small (1-50)
Products
DiNA-001 (lead preclinical cardiac gene therapy program)
A preclinical gene therapy program targeting MYBPC3-linked hypertrophic cardiomyopathy intended to restore or correct gene function in cardiac muscle.
DiNA-001 (lead preclinical cardiac gene therapy program)
A preclinical gene therapy program targeting MYBPC3-linked hypertrophic cardiomyopathy intended to restore or correct gene function in cardiac muscle.
Services
Development and commercialization of biomanufacturing and scale-up services for viral vectors and genetic medicines to support preclinical through commercial supply.
Design, development and production services for catheter-based delivery devices intended to enable localized, loco-regional delivery of gene therapies to the heart and other organs.
Collaborative discovery and screening service to identify cardiac-targeting capsid variants using engineered heart tissue assays, capsid libraries and preclinical models.
Development and commercialization of biomanufacturing and scale-up services for viral vectors and genetic medicines to support preclinical through commercial supply.
Design, development and production services for catheter-based delivery devices intended to enable localized, loco-regional delivery of gene therapies to the heart and other organs.
Collaborative discovery and screening service to identify cardiac-targeting capsid variants using engineered heart tissue assays, capsid libraries and preclinical models.
Expertise Areas
- Cardiac gene therapy development
- Capsid engineering and vectorology
- Engineered heart tissue and iPSC disease modeling
- Catheter-based delivery systems and loco-regional perfusion
Key Technologies
- Adeno-associated virus (AAV) vectors
- Adenoviral and helper-dependent adenoviral vectors
- Capsid library screening and engineering
- Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes